[Min Ji-Son, Edaily Reporter] South Korean pharmaceutical, biotech, and healthcare stocks experienced a turbulent trading session on November 17 as the release of global Phase 3 trial results for AriBio’s oral Alzheimer’s disease drug candidate, AR1001, triggered sharp swings in the shares of companies linked to the drugmaker.
AriBio Lab and AriBio Holdings both fell to their daily lower trading limits, while Samjin Pharmaceutical also suffered a steep decline. Although AR1001 met its primary efficacy endpoint in the monotherapy population, it failed to demonstrate statistically significant efficacy in the overall study population.
Given the high expectations surrounding the trial, the failure to establish efficacy across the broader patient population appeared to weigh heavily on investor sentiment. AriBio Lab stock trend on Nov. 17. (Image = MP Doctor) According to KG Zeroin’s MP Doctor platform, AriBio Lab closed at 4,070 won on the KOSDAQ, down 29.95%, or 1,740 won, from the previous session.
AriBio Holdings stock trend on Nov. 17. (Image: MP Doctor) AriBio Holdings also ended regular trading at 2,560 won, down 29.86%, or 1,090 won.
Samjin Pharmaceutical stock trend on Nov. 17. (Image = MP Doctor) Samjin Pharmaceutical initially gained more than 11% in pre-market trading. Its shares climbed as high as 21,250 won during the session before reversing course and closing at 17,030 won, down 15.48%, or 3,120 won.
All three listed companies have equity or business ties to AriBio, the privately held developer of AR1001. Since AriBio itself is not publicly traded, investor expectations regarding the drug’s clinical development have been reflected in the stock prices of AriBio Lab, AriBio Holdings, and Samjin Pharmaceutical.
AriBio Lab, formerly known as the CHA Vaccine Institute, conducts research and development in vaccines and immunology. AriBio and AriBio Holdings acquired stakes in the company by participating in its capital increase. AriBio Holdings is a major shareholder of AriBio Lab and also holds a stake in AriBio itself. According to its semiannual report, AriBio Holdings owns 13.42% of AriBio.
Samjin Pharmaceutical is AriBio’s second-largest shareholder, with a 5.47% stake. It also has an agreement with AriBio to jointly conduct the South Korean Phase 3 trial of AR1001 and holds exclusive domestic manufacturing and commercialization rights.
The global Phase 3 trial of AR1001, known as POLARIS-AD, enrolled 1,535 patients with early-stage Alzheimer’s disease.
Among the two prespecified analysis populations, the monotherapy population consisted of 604 patients who were not taking existing symptomatic treatments, including acetylcholinesterase inhibitors such as donepezil or memantine.
At 52 weeks, the monotherapy population receiving AR1001 showed a 0.44-point slower rate of deterioration on the Clinical Dementia Rating–Sum of Boxes (CDR-SB) scale compared with placebo, a statistically significant difference (p=0.0266).
In contrast, the difference in the overall study population was only 0.11 points and did not reach statistical significance (p=0.4015).
The trial was designed to evaluate the overall population and the monotherapy population as two separate, prespecified primary analysis populations. Meeting the predefined statistical threshold in either population was sufficient to satisfy the trial’s primary efficacy objective.
Based on the monotherapy results, AriBio announced that its Phase 3 trial had met its primary objective.
Investors, however, appeared more concerned about the failure to demonstrate efficacy in the overall population and whether the monotherapy data alone would be sufficient to support regulatory approval and subsequent commercialization.
In a letter to shareholders released Tuesday, AriBio highlighted the positive findings in the monotherapy population.
“We achieved statistical significance in the prespecified monotherapy population, which was established following prior discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA),” the company said. “We have therefore met the primary efficacy objective that defines the success of the Phase 3 trial.”
"Management believes that the monotherapy results alone provide a basis for pursuing an FDA marketing application," it added. "The specific regulatory pathway and requirements will be determined through discussions with the FDA."
An AriBio official said the extension study remains underway and is scheduled to continue through June of next year, with additional analyses of secondary endpoints and biomarkers also planned.
"We do not consider this trial a failure," the official said. "The study was designed to evaluate the overall population and the monotherapy population separately, with the primary efficacy objective considered met if either population satisfied the predefined statistical criteria."
AriBio also plans to initiate preliminary regulatory meetings, including a pre-New Drug Application (Pre-NDA) meeting with the FDA, to discuss potential approval pathways with regulators in the United States and Europe.
The company highlighted AR1001’s potential advantage in treatment convenience compared to existing Alzheimer’s therapies.
In its shareholder letter, AriBio compared the oral drug with lecanemab, marketed under the brand name Leqembi.
"Lecanemab requires intravenous infusions every two weeks or weekly subcutaneous injections, along with regular MRI monitoring for amyloid-related imaging abnormalities (ARIA), including brain swelling and microhemorrhages," the company said.
“AR1001, by contrast, is a once-daily oral tablet that allows patients to continue treatment as part of their daily lives without having to repeatedly visit hospitals for injections.”
There are precedents in which the FDA granted approval for a specific patient population after Phase 3 trials produced divergent results between the overall study population and a prespecified subgroup.
Eli Lilly’s breast cancer treatment Inluriyo (imlunestrant) failed to demonstrate a statistically significant improvement in progression-free survival (PFS) in the overall Phase 3 study population but showed a significant benefit in a prespecified population of patients with ESR1 mutations.
The FDA granted approval last year, limiting the indication to patients with ESR1-mutated advanced or metastatic breast cancer.
Similarly, vepdegestrant, a breast cancer treatment jointly developed by Pfizer and Arvinas, did not meet the statistical significance threshold for PFS improvement in the overall Phase 3 population but demonstrated a significant benefit in patients with ESR1 mutations.
The FDA approved the drug this year for patients with ESR1-mutated advanced or metastatic breast cancer.
Meanwhile, Samjin Pharmaceutical stated that its domestic commercialization strategy would depend on AriBio’s next steps.
"The domestic regulatory approval process will also need to be led by AriBio," a Samjin Pharmaceutical official said. "We plan to discuss our domestic commercialization roadmap once AriBio determines its development and regulatory strategy moving forward."
As the government considers hostile mergers and acquisitions (M&A) as a means to enhance corporate value, calls are growing for the establishment of institutional safeguards before revitalizing the ac…
Samyang Round Square, the holding company of SamyangFoods(003230), has established a wind power generation subsidiary in Pyeongchang, Gangwon Province. This move is intended to pursue a “repowering” p…
South Korean pharmaceutical, biotech, and healthcare stocks experienced a turbulent trading session on November 17 as the release of global Phase 3 trial results for AriBio’s oral Alzheimer’s disease …